10x Genomics, Inc. Earnings Recaps
Q3 2025
Nov 7, 2025
10X Genomics reported a solid third quarter, exceeding revenue expectations with $149 million driven by strong demand for both single-cell and spatial biology products despite ongoing macroeconomic challenges.
Key takeaways
- Total revenue of $149 million surpassed guidance, reflecting strong execution amid macro pressures.
- Significant year-over-year growth in spatial consumables, particularly for Xenium, continued to drive momentum.
- Expansion of product offerings, including new Chromium Flex and Xenium protein, is anticipated to enhance market adoption and streamline workflows.
- Ended the quarter with a robust $482 million cash position, ensuring flexibility for strategic investments.
- Customer sentiment indicates sustained cautious spending behavior, particularly concerning capital expenditures.